The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab

RA patients could be easily stratified prior to therapeutic intervention with two molecules related to the pathway blocked by tocilizumab. G1 patients, who had the best response to tocilizumab, had the highest level of IL-6 and the lowest level of sIL-6R.